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ABSTRACT
In most countries, as many as 15 to 25% of the adult population have raised
blood pressure. People with hypertension, and even those with mild elevation
of blood pressure, are at an increased risk of cardiovascular disease, whether
or not the symptoms are present. The risk of serious cardiovascular disease
varies greatly among individuals and is also determined by a variety of
concomitant risk factors other than the level of blood pressure.
Hypertension develops as a result of disturbances of the body's blood
pressure regulating system. The biological activity of the renin-angiotensin
systems results from a series of specific enzymatic cleavages leading to the
generation of angiotensin II, a potent vasoconstrictor.
In the treatment of hypertension, inhibition of the angiotensin converting
enzyme is established as one modern therapeutic principle. Angiotensin
converting enzyme inhibitors act by inhibiting the conversion of angiotensin I
to angiotensin II.
The in vitro assay, developed by ELBL and WAGNER (1991) for the detection
of angiotensin converting enzyme inhibitors in plant extracts was successfully
established during this study. Plants used by traditional healers in South Africa
for the treatment of high blood pressure were investigated for their anti-
hypertensive properties, utilizing the established angiotensin converting
enzyme assay.
Twenty plants were investigated for their angiotensin converting enzyme
inhibitory activity. The highest inhibition (97%) was obtained by Adenopodia
spicata leaves. A further seven plants exhibited an inhibition greater than
70% and five more over 50%.
Plants exhibiting inhibition levels greater than 50% were further tested for the
presence of tannins in order to eliminate possible false positives.
The leaves of Tulbaghia violacea were chosen for bioassay-guided
fractionation in an attempt to isolate the active compound(s).
Serial extractions were made of ground Tulbaghia violacea leaves using polar
to non-polar solvents to establish the solvent giving optimum extraction of the
active compound(s). Distilled H2O was selected as the extractant and a bulk
extract was performed on 0.7 kg ground leaves. The extracted residue was
partitioned against butanol, fractionated using cation exchange resin
chromatography, Sephadex ® LH-20 and high performance liquid
chromatography. Fractions collected after each purification step were assayed
using the angiotensin converting enzyme assay. Fractions exhibiting high
levels of angiotensin converting enzyme inhibition were selected for further
purification. The active fraction from the final high performance liquid
chromatography step used in this study requires further attention in order to
purify and identify the active compound(s). The chromatographic and chemical
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1.1 Role of Plants in Health Care
In most countries, as many as 15 to 25% of the adult population have raised
blood pressure. Cardiovascular disease causes the greatest mortality of
humans in the USA and remains a major health problem world wide (YANG,
MERRILL, THOMPSON, ROBBILLARD and SIGMUND, 1994). People with
hypertension, and even those with mild elevation of blood pressure, are at an
increased risk of cardiovascular disease, whether or not the symptoms are
present.
In America, 90% of the population suffering from a form of cardiovascular
disease suffer from hypertension (YANG, MERRILL, THOMPSON,
ROBBILLARD and SIGMUND, 1994). The risk of serious cardiovascular
disease varies greatly among individuals and is also determined by a variety
of concomitant risk factors other than the level of blood pressure
(ZANCHETTI, CHALMERS, ARAKAWA, GYARFAS, HAMLET,
HANNSSON, JULUIS, MACMAHON, MANCIA, MENARD, OMEA, REID
and SAFAR, 1993).
It is thought that about 80% of the 5 200 million people of the world live in
developing countries. The World Health Organization estimates that about
80% of these people rely almost exclusively on traditional medicine for their
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primary health care needs. Since medicinal plants are the "backbone" of
traditional medicine, this means that more than 3 300 million people in the
developing countries utilize medicinal plants on a regular basis
(FARNSWORTH, 1994). With up to 500 000 species of higher plants known
to exist on our planet, common sense dictates that many more useful drugs
remain to be discovered from this source .
Traditional medicine is an integral part of South African cultural life, a position
that is unlikely to change to any significant degree during the years to come
(BRANDT, OSUCH, MATHIBE and TSIPA, 1995). It is estimated that between
12 and 15 million South Africans still depend on traditional herbal medicines
from as many as 700 indigenous plant species (MEYER, AFOLAYAN,
TAYLOR and ENGELBRECHT, 1996).
People suffering from hypertension are typically treated for the duration of their
lives. With the soaring prices of Western medicines already beyond the grasp
of large proportions of the world's population, it would seem that the demand
for low-cost effective remedies would be on the increase. It is thus essential
that traditionally used plants be scientifically investigated and evaluated as to
their future role in the health care systems of the world. By studying traditional
medicines, many conditions that have previously been incurable may soon be
treated with low-cost medicines.
1.2 Hypertension
Despite many years of research into the physiological mechanism regulating
blood pressure, the primary causative determinants of hypertension remain
elusive. Hypertension develops as a result of disturbances of the body's blood
pressure regulating system. The level of the blood pressure is determined by
3
the diameter of the small arteries and arterioles (resistance vessels) and by
the cardiac output. The latter can change owing to (a) inotropic effects on the
heart itself; (b) alterations in blood volume and body electrolyte composition
due, for example, to changes in renal function, and (c) through the effects on
the venous capacity. During normal circulatory homeostasis the heart, kidney,
vascular diameter and the veins are all influenced by (a) the activity of the
autonomic nervous system; (b) various circulating hormones; and (c) a
number of local hormones (KORNER.1982).
1.3 The Renin-Angiotensin System
By exploring the means by which normotension is maintained by the renin-
angiotensin system (RAS), an understanding into how the treatment of
hypertension using angiotensin converting enzyme (ACE) inhibitors can be
achieved. The best known functions of angiotensin II are its contributions to
cardiovascular and renal homeostasis. In its classic definition, the RAS
maintains blood pressure through angiotensin II (LEE, BOHM, PAUL and
GANTEN, 1993). It is a complex and mixed enzyme-hormonal system that
plays an important role in blood pressure regulation and fluid and electrolyte
homeostasis (KANG, LANDAU, EBERHARDT and FRISHMAN, 1994).
1.3.1 Historical Overview
Renin was discovered in 1898 (TIGERSTEDT and BERGMAN, 1898).
GOLDBLATT, LYNCH, HANZAL and SUMMERVILLE (1934) demonstrated
that constriction of a renal artery in dogs could induce hypertension. MERRILL,
WILLIAMS and HARRISON (1938) reported a pressor/vasoconstrictor
response to the injection of an alcohol extract of rat renal cortex in
anaesthetised rats. The effect was independent of the presence of various
organs and was evident in the isolated rat leg. Also in 1938, FASCIDO,
HOUSSAY and TAQUINI induced a rapid and substantial rise in arterial
pressure by grafting an ischemic kidney into the neck of adrenalectomized and
nephrectomized dogs.
Thus by the end of the 1930's it was clear that an ischemic kidney could
release a pressor substance. The vasoactive end product, which had a more
rapid pressor action, was discovered almost simultaneously by two groups.
The name given to this active octapeptide was angiotensin I. The roles of
angiotensin and ACE in the formation of angiotensin II were defined.
Angiotensin II became available for infusion upon the elucidation of its amino
acid sequence in 1956 and its synthesis in 1957. In the late 1950's and early
1960's, it became clear that aldosterone secretion could be simulated by
angiotensin II. In the 1960's and 1970's, angiotensin II was considered by
many to be a major secretagogue of aldosterone (NICHOLLS, CHARLES,
CROZIER, ESPINER, IKRAM, RADEMAKER, RICHARDS and YANDLE,
1994).
HABER, KOERNER, PAGE, KLIMAN and PURNODE (1969) described a
radioimmunoassy method for quantifying renin activity in plasma. The assay
of the activity and concentration of renin improved the awareness and
understanding of the circulating RAS under physiological and patho-physical
circumstances (NICHOLLS, CHARLES, CROZIER, ESPINER, IKRAM,
RADEMAKER, RICHARDS and YANDLE, 1994).
More of a stumbling block, was, and still is, the accurate determination of
circulating levels of angiotensin II. Few laboratories today can claim to
measure angiotensin II levels in plasma with great accuracy and precision
(NUSSBERGERand BRUNNER, 1993). By the 1970's, it became evident that
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through angiotensin II, the RAS could induce vasoconstriction and stimulate
aldosterone secretion.
1.3.2 Outline of the Renin-Angiotensin System
The biological activity of the renin-angiotensin systems results from a series
of specific enzymatic cleavages of polypeptide precursors leading to the
generation of angiotensin II and related peptides (Figure 1). Renin, a
glycoprotein, initiates this sequence by cleaving the leu10-val11 bond of the
globular protein angiotensin, to liberate angiotensin I. Renin occurs mainly in
the kidneys where it is stored in intracellular granules of the juxta glomerular
cells (LIN and FRISHMAN, 1996). Its release appears to be in response to a
variety of normal or abnormal phenomena that reduce arterial blood pressure,
renal perfusion, or sodium chloride load in the distal renal tube (DAVIS and
FREEMAN, 1976). In the second step, angiotensin I is cleaved by vascular
endothelial ACE, and a dipeptide unit is split off to give the physiologically
active octapeptide angiotensin II (LIN and FRISHMAN, 1996). Angiotensin
II is destroyed rapidly by the enzymes grouped as angiotensinases, its half life
in humans being 1-2 minutes. The angiotensinases include an
aminopeptidase that removes the asparagine residue from the N-terminal of
angiotensin II resulting in angiotensin III. The metabolism of angiotensin III
yields several inactive by-products (GREENWALD and BECKER, 1994).
Angiotensin II is a potent constrictor of vascular smooth muscle and stimulates
aldosterone biosynthesis in the adrenal zone glomerulosa. It also has well
defined effects on the adrenal medulla, sympathetic ganglia, Na+ handling by
the kidney and perhaps central nervous actions on blood pressure control,
thirst and salt appetite. Many of these actions seem to be related to blood
































Figure 1: The renin angiotensin system . The release and physiological effects of angiotensin II and its degradation .
Adapted from KELLOW (1994) and HANSEN, NYMAN, WAGENER SMITT, ADSERSEN, GUGIKSEN,
RAJASEKHARAN, and PUSHPANGADAN (1995).
water homeostasis. Aldosterone is a potent mineralocorticoid which promotes
Na+ retention and K+ loss from epithelia (MENDELSOHN, 1982).
1.3.3 Molecular Biology of the Renin-Angiotensin System
Historically, the RAS system has been viewed as a systemic one, that being
the different components have been derived from different organs and
delivered to the site of action by the circulatory system (GRIENDLING,
MURPHY and ALEXANDER, 1993).
Conceptionally, two kinds of RAS's exist (DZAU, 1988)(Figure 2): (a) a
circulating endocrine RAS responsible for short-term cardiorenal
homeostasis; and (b) local renin-angiotensin systems present in many local
tissues where these systems exert autocrine and paracrine influences on local
tissue function which is influenced by the intrinsic tissue renin-angiotensin
system.
Recently, using molecular and biochemical approaches to angiotensin
physiology, the possibility that there are distinct local RAS's with different
mechanisms of regulation has been proposed. Local RAS's have been
proposed in the vasculature, brain, heart and kidney, but conclusive evidence
for the existence of all components of the system in physiologically relevant
amounts and relationships remain elusive. It is thought that this localisation of
the RAS may serve as a mechanism for limiting the actions of angiotensin II
to a specific organ or physiological event (GRIENDLING, MURPHY and
ALEXANDER, 1993).
Indirect evidence for a local RAS has been derived from whole animal,
isolated organ and tissue culture studies. Evidence against the existence of
a complete local RAS is based largely on the observation that a bi-lateral
nephrectamy caused a dramatic decease in arterial renin activity, suggesting
that the renin- like activity associated with the vascular wall is derived from
uptake of circulatory renin of renal origin (GRIENDLING, MURPHY and
ALEXANDER, 1993). In support of this, it has been demonstrated using
molecular biological techniques, that arterial tissues posses low levels of renin
mRNA, with it being totally absent in other studies. Finally, it is unclear whether
the angiotensinogen mRNA present in the vasculature is associated with
smooth muscle and endothelium or merely with adherent adipose tissue














-> Angiotensin I -> Angiotensin II Local Action
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Figure 2: Circulating renin-angiotensin system vs. local renin-angiotensin
system: interactions and possible angiotensin generation sites
(DANSER, 1996).
9
It is hypothesised that angiotensin II produced locally influences local tissue
function and structure such as vascular tone, cardiac contractibility and mass,
renal hemodynamics and sodium handling (LEE, BOHM, PAUL and GANTEN,
1993). This has been confirmed by studies which demonstrated the beneficial
effects of ACE with respect to their anti-hypertensive, antiproliferative and
cardioprotective impact, which is apparently independent of converting
enzyme inhibition in plasma (LEE, BOHM, PAUL and GANTEN, 1993).
Differentially regulated gene expression within several tissue - RAS's has been
demonstrated in various animal models of hypertension. These data may
provide further insight into the regulation of the RAS on a tissue level and may
help clarify the physiological significance of the tissue RAS (LEE, BOHM,
PAUL and GANTEN, 1993).
1.3.4 Molecular Genetical Approach
Many studies have been carried out on the population distribution and
hereditary nature of hypertension since the first reliable measurements of
blood pressure were made. Blood pressure is a quantitative trait, which varies
continuously throughout the whole population. The regulation of blood
pressure is controlled by a variety of mechanisms that involve several genetic
loci and environmental factors (CORVOL, JEUNEMAITRE, CHARRU,
KOTELEVTSEVandSOUBRIER, 1995). Not much is known about how these
genes regulate blood pressure in humans, and exactly which genes are
actually involved in hypertension or the contributions that the environment
makes with respect to the genetic regulation.
A number of studies have shown that both genetic predisposition and
environmental factors govern individual blood pressure levels. The heritable
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component of blood pressure has been documented in familial and twin
studies. The evidence suggests that approximately 30% of the variable blood
pressure is hereditary and 50% can be attributed to the environmental
influences (WARD, 1990). This makes it complicated when trying to unravel
the fundamentals of this disease, as it is influenced by both genetic and
environmental factors.
Through molecular genetic studies, the contributions made by the RAS genes
to blood pressure variance in animals and humans can be evaluated. Studies
that have been carried out, conclude that it is possible that neither renin nor
the ACE genes contribute to a large extent to genetic hypertension, at least in
humans. They could, however, be involved in cases in humans that are yet to
be defined. Molecular variants of the angiotensinogen gene constitute
inherited predispositions to essential hypertension in humans, and are likely
to be involved in some cases of pregnancy-induced hypertension. An ACE
gene polymorphism associated with an increase in plasma and tissular ACE
levels appears to be a strong marker of coronary and cardiac disease
(CORVOL, JEUNEMAITRE, CHARRU, KOTELEVTSEV and SOUBRIER,
1995). The genetic approach will lead to an understanding of genomic risk
factors in hypertension and may identify control systems, which are presently
unknown, which will lead to a new approach to the prevention of
cardiovascular death.
1.4 Blockage of the Renin-Angiotensin System
It's evident when observing the RAS, that blocking or inhibition of enzymes at
specific points in the pathway would result in the reduction or removal of
angiotensin II and hence improve the ability to treat and understand
hypertension caused by this system.
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1.4.1 Sites at which the RAS may be Blocked
Theoretically , there are a number of sites at which the RAS might be blocked
(Table 1). So far no direct inhibitors of renin biosynthesis or renin maturation
are available. The inhibition of renin secretion by p -adrenoceptor blockers is
incomplete. Furthermore, since (3 -blockers have many more actions beyond
renin suppression, responses elicited by them cannot be taken accurately to
reflect inhibition of the RAS (NICHOLLS, CHARLES, CROZIER, ESPINER,
IKRAM, RADEMAKER, RICHARDS and YANDLE, 1994).
Table 1: Reaction sites available for inhibition of the renin-angiotensin system
(NICHOLLS, CHARLES, CROZIER, ESPINER, IKRAM,
RADEMAKER, RICHARDS and YANDLE, 1994).













Peptide and peptide mimetic renin inhibitors
Captopril, enalapril and lisinopril
Saralasin and similar peptides
Imidazole derivatives (losartan)
Efforts have and are continuously being made to improve the quality of the
drugs available on the market. As can be seen in the above table, there are
three sites at which drugs have been directed in order to block the RAS, these
being renin, ACE and angiotensin II receptor inhibitors. There is much debate
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as to the site which offers the greater control of the RAS system with the
presence of minimal side effects.
1.4.2 Renin Inhibition
The search for compounds which block the formation of renin, has involved
the development of four classes of compounds, namely renin antibodies
(antisera, monoclonal antibodies, Fab fragments), synthetic derivatives of the
prosegment of the renin precursor, pepstatin analogs and angiotensinogen
analogs.
The renin antibodies were the first class of renin inhibitors developed, which
acted directly against the enzyme. Although shown to be effective through
lowering of the blood pressure and plasma renin activity, this immunological
approach is limited because the antibodies are orally inactive as a result of
their inability to be absorbed intact from the gastrointestinal tract. With
repeated intravenous administration, the antibodies can induce antigenic
reactions (LIN and FRISHMAN, 1996).
The next class of renin inhibitors developed were based on structure-activity
relations. These inhibitors would bind tightly to renin and would not be cleaved
by renin proteases or any other proteases. From this principal, the third class
of renin-inhibiting drugs were modelled on the activity of pepstatin, a natural
pentapeptide that universally inhibits aspartyl protease enzymes with a high
inhibitory potency for pepsin and a low inhibitory activity for renin. These
analogs, however, exhibited poor specificity and affinity for human renin, and
this has limited their experimental and potential clinical use (LIN and
FRISHMAN, 1996).
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The fourth class of renin inhibitors, the angiotensinogen (substrate) analogues
holds the greatest promise. By replacing specific bonds within the human
angiotensinogen molecule, potent inhibitors of renin have been produced.
Extensive studies have been made of the interaction of the active sites and
subsites of renin with angiotensinogen analogs incorporating statin as well as
other transition state analogs, replaced at various substrate analog subsites.
Renin inhibition has potential therapeutic efficacy in the treatment of
renovascular hypertension and congestive heart failure. However, renin
inhibition may also demonstrate clinical utility in a number of other clinical
scenarios. Conditions such as stroke, renal trauma and acute closure of renal
artery grafts are all associated with high plasma renin levels (LIN and
FRISHMAN, 1996). Significant adverse reactions have not yet been observed.
Further research for the development of an agent with good oral bio-availability
for patient treatment is being carried out.
1.4.3 Angiotensin Converting Enzyme Inhibition
Angiotensin converting enzyme inhibitors act by inhibiting the conversion of
angiotensin I to angiotensin II. On the basis of chemical structure, they can be
divided into three distinct groups; the sulfhydryl-containing agents (e.g.
captopril), the non-sulfhydryl-containing agents and the phosphinic acid
derivatives (e.g. fosinopril). Captopril and fosinopril bind to the zinc ion in the
ACE molecule through their sulfhydryl and phosphinic acid moieties
respectively, whereas the other agents bind to the zinc ion through carboxyl
residues (KELLOW, 1994).
Angiotensin converting enzyme inhibitors are considered effective and safe for
the treatment of hypertension; their anti-hypertensive effect being enhanced
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by a low salt diet. Their pharmacological effects are vasodilation, increased
sodium excretion, diuresis and lowering of blood pressure (ABRAMS, DAVIES
and FERGUSON, 1984). They reduce the mortality in patients with heart
failure and prevent progressive post-infarct heart failure. They are also well
tolerated, and have a good safety profile. There is little doubt that ACE
inhibition does enhance the action of bradykinin. There are theoretical grounds
linking this to the development of cough and some preliminary evidence
relating this to angio-oedema (SUNMAN and SEVER, 1993). ACE inhibitors
are not safe in pregnancy, and as soon as pregnancy is determined, an
immediate switch must be made (OPIE, 1996) (ii).
Recently ELBL and WAGNER (1991) introduced an in vitro assay for the
detection of ACE inhibitors in plant extracts. Angiotensin converting enzyme
is believed to be the rate-limiting step in angiotensin II formation by the RAS.
This method is based on the ACE-catalysed cleavage of the chromophore-
fluorophore labelled substrate, dansyltriglycine, into dansylglycine, which is
quantitatively measured by HPLC (Figure 3). By utilizing this technique, plant
species that are used in traditional medicines to treat hypertension can be
effectively screened, and their level of ACE inhibition determined.






Figure 3: Dansyltrigylcine is cleaved by ACE into dansylglycine, which can be
quantified by HPLC (ELBL and WAGNER, 1991).
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1.4.4 Angiotensin II Inhibition
Angiotensin II receptor antagonists have been developed (VELASQUEZ,
1996). Angiotensin receptors can be placed into two distinct subtypes. These
are the type 1 angiotensin receptor (AT1) and type 2 angiotensin receptor
(AT2). Both of these receptor subtypes are apparently found in all tissues, in
varying proportions (KANG, LANDAU, EBERHARDTand FRISHMAN, 1994).
The AT1 receptor is found in virtually all vascular tissue, and is the only type
present in the rat liver and spleen. The AT2 subtypes exhibit different
distributions in other tissues.
The first blockage achieved in man was through the use of peptide analogues
of angiotensin II. Saralasin is a partial antagonist and required intravenous
infusion (NICHOLLS, CHARLES, CROZIER, ESPINER, IKRAM,
RADEMAKER, RICHARDS and YANDLE, 1994). Saralasin's clinical
usefulness as a long term anti-hypertensive agent is limited by its short half-
life, significant agnostic properties and lack of oral bio-availability ( KANG,
LANDAU, EBERHARDTand FRISHMAN, 1994).
Several new non-peptide imidazole angiotensin II receptor antagonists that
have potential anti-hypertensive properties have been developed. These novel
compounds have a high affinity for AT1 and have no agnostic activity
(VELASQUEZ, 1996). These compounds are also non-peptides, and can thus
be taken orally. Losartan was the first antagonist of this type to become
available for clinical use and has been the most extensively studied. It
selectively inhibits angiotensin II binding in animal and human tissues, and
blocks the pressor effects of exogenously administered angiotensin II in
animals (VELASQUEZ, 1996).
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Many more angiotensin II antagonists are undergoing clinical trails and are in
various stages of development. The availability of non-peptide angiotensin II
receptor blockers have provided an alternative in the treatment of
hypertension. Current data suggest that these receptor blockers maybe useful
as initial monotherapy for mild to moderate hypertension, or in patients whose
blood pressure is not controlled with thiazide therapy (VELASQUEZ, 1996).
1.5 Feasibility of Research
There is debate as to whether it is economically feasible to successfully
introduce renin inhibitors into the cardiovascular market due to the fact that
ACE inhibitors are becoming generic and increasingly cheaper. Angiotensin
converting enzyme inhibitors are also considered by many to be the best
treatment for hypertension and congestive heart failure. With the success of
ACE inhibitors and the impending success of AT2 antagonists, would it be
possible for renin inhibitors to demonstrate their cost effectiveness? Unless
companies are prepared to respond to the challenge and take risks, ACE
inhibitors, probably in conjunction with angiotensin II receptor antagonists, will
remain the state of the art drugs for the treatment of hypertension and many
other cardiovascular diseases (WOOD and CLOSE, 1996).
1.6 Hypertension in South Africa
SEEDAT (1996) estimated that in the early 1990's , six million cases of
hypertension were documented in South Africa. Mortality related to
hypertension has for many decades occurred most commonly in the urban
South African black community (STEYN, FOURIE, LOMBARD,
KATZENELLENBOGEN, BOURNE and JOOSTE, 1996). Ten percent of the
mortalities reported on the death certificates from Johannesburg's city health
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department in 1970, were cardiovascular deaths, mainly due to hypertension
(SEFTEL, JOHNSON and MULLER, 1980).
Surveys carried out among urban black South Africans reflect high rates of
hypertension. SEFTEL, JOHNSON and MULLER (1980) reported that
hypertension, defined as a diastolic blood pressure above 90 mmHg, occurred
in about 33% of both gender groups in Johannesburg blacks.
SEEDAT, SEEDAT and HACKLAND (1982) reported that in Durban, 23% of
males and 27% of females had a blood pressure of over 160/95 mmHg
compared with the 9% of males and 10% of females living in rural areas.
These studies were all carried out in the 1970's and 1980s.
MOLLENTZE, MOORE, STEYN, JOUBERT, STEYN, OOSTHUIZEN and
WEICH (1995) have shown that the difference between the incidence of
hypertension in urban and rural South African blacks has become less
pronounced during the 1990's. In a study conducted in a semi-rural area,
QwaQwa, the rate of hypertension was 29%, compared with 30.3% in
Mangauga, a black township outside Bloemfontein. These results could be
due to the fact that rural communities are disappearing throughout South
Africa and that the factors influencing the levels of hypertension can now be
found in the semi-rural and urban settings. This could be due to the migration
of rural people to the urban areas.
Comparison of hypertensive and normotensive participants in the study carried
out by STEYN, FOURIE, LOMBARD, KATZENELLENBOGEN, BOURNE and
JOOSTE (1996) confirmed that factors such as alcohol use and obesity were
associated with hypertension. They also found that in some cases there was
an indication that participants who were of a higher socio-economic standing
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were more frequently hypertensive than those who were not. Such
hypertension phenomenon has also been found in urbanised migrant Indian
communities (STEYN, FOURIE, LOMBARD, KATZENELLENBOGEN,
BOURNE and JOOSTE, 1996). If this increased rate of hypertension is not
addressed, the occurrence of strokes and heart attacks will become as
common in the urban black South Africans, as they already are in the other
population groups.
There is a racial difference in the prevalence of hypertension, but whether it
is due to genetics or other factors remains to be determined. There is a
statistical difference in the prevalence of hypertension between Zulus, Whites
and Indians of Durban. The blacks in the Transvaal also have a high
prevalence of hypertension, as does the "mixed" race group in the Cape
(SEEDAT, 1996).
1.7 Guidelines for the Management of Mild Hypertension
When managing hypertension, the present guidelines concentrate on mild
hypertension, as this condition often presents a diagnostic and therapeutic
problem, and there is clear evidence in the benefit of treating more severe
hypertension. Patients suffering from hypertension differ with respect to age,
blood pressure elevation, organ damage and concomitant risk factors and
diseases and they live in societies in which cardiovascular risk and economic
resources differ widely.
1.8 The Blood Pressure Limits
A guideline used to determine cases of hypertension is that of the use of
blood pressure limits. The basic concept is that blood pressure elevation
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results in risks, which increase as blood pressure rises. This is particularly well
established in the case of strokes, although it also holds for heart diseases
(OPIE, 1996) (i). It has been suggested that simple diastolic and systolic blood
pressure limits be utilised to be used as a guideline in determining patients
with respect to risk categories (Table 2).




















Diastolic blood pressure Systolic blood pressure
The higher the blood pressure values, the more essential it is for the patient
to be issued with drugs and earlier referral. In cases when malignant
hypertension is suspected, same day referral is required ( OPIE, 1996) (i).
Furthermore, patients with increased blood pressure levels, whether diastolic,
systolic, or both, are advised to modify their lifestyle.
When dealing with hypertension, it is imperative that treatment commence as
soon as possible. With the never-ending flow of rural inhabitants into urban
areas, along with the ever increasing levels of stress present in a modern
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lifestyle, drugs used in the treatment of hypertension must be developed that
must be as effective as those already on the market, but at more competitive
prices.
1.9 Aims and Objectives of this Study
The aims of this project were to establish and optimise the in vitro assay
developed by ELBL and WAGNER (1991) for the detection of ACE inhibitors.
Plants used by traditional healers in South Africa for the treatment of high
blood pressure were investigated for their potential anti-hypertensive
properties, utilizing the ACE assay. Plants that exhibit high levels of ACE
inhibitory activities were tested to determine their level of tannin content. This
was carried as tannins interacting with the ACE enzyme assay could cause
false positive results. A plant exhibiting low or no tannin content and high ACE
inhibitory activity was subjected to bulk extraction and an attempt was made
to isolate the active compound(s) using bioassay-guided fractionation.
By investigating the ACE-inhibitory activity of plants in traditional use, this
project formed part of an initiative for the assessment of herbal medicines as
safe and efficient remedies for treatment of hypertension, evaluated according





All chemicals and reagents needed for the project were purchased from
Sigma. Solvents used were obtained from Saarchem, South Africa; Univar,
South Africa; BDH Laboratory Suppliers, England; Merck and Associated
Chemical Enterprises, South Africa.
2.2 Plant Material
All plants were collected from Natal, South Africa during January and February
1997. The exact sources are shown in Table 3. The plants collected were
chosen following literature searches (HUTCHINGS, SCOTT, LEWIS and
CUNNINGHAM, 1996) and voucher specimens were deposited at the
Herbarium, Department of Botany, University of Natal, Pietermaritzburg (Table
3).
After collection, barks and roots were immediately oven dried at 50 °C for 96
hours. All other plant parts were oven dried at 50 °C for 48 hours. The dried
material was subsequently ground and stored in the dark in airtight containers
at room temperature until extraction.
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2.2.1 Extraction of Plant Material
Plant material was ground to a fine powder using a homogenizer. Half of the
ground plant material (200 mg) was extracted in 5 ml ethanol and the other
half in 5 ml water for 60 minutes using a sonicator. Ethanolic and aqueous
extracts were performed for each plant part. The extracted liquid was passed
through a funnel lined with Whatman No.1 filter paper to filter off all debris.
The liquid was collected and re-filtered through a DynaGard 0.22 /̂ m filter. The
liquid was placed in pre-weighed pill vials and evaporated to dryness using a
fan. The pill vials were then re-weighed and the weight of the residues was
determined.
2.2.2 Preparation of Plant Extracts for ACE Assay
Solutions of inhibitors extracted in water were made by dissolving 1 mg of test
compound in 1 ml HEPES assay buffer (Appendix 1). Inhibitors extracted
using ethanol, were dissolved in HEPES assay buffer containing 10% ethanol.
The same applied for all other organic solvents used in the extraction process.
The final concentration was 0.33 mg of test compound in 1 ml assay volume.
Table 3: Plants collected for screening for the presence of angiotensin
converting enzyme (ACE) inhibitors.
Plant Species
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Rhus chirindensis Bak. f.
Sclerocarya birrea (A. Rich.)




































































































Key: ba: bark r: roots
s: stem I: leaves
bu: bulbs UN: University of Natal, Pietermaritzburg, Herbarium
A: Botany Department, University of Natal, Pietermaritzburg
B: Botanical Gardens, Pietermaritzburg
S: Silverglen Nursery, Durban
f: Gastro-intestinal
fd: Includes uses for diarrhoea/dysentery
h: Debility - tonics, blood purifiers, liver complaints, anthrax infection
hd: diabetes
k: Febrile - colds, fever, influenza, malaria
m: Cardiac - heart, blood pressure
p: Swellings, growths, warts/ haemorrhoids, scrofula, dropsy
2.3 Synthesis of Dansyltriglycine
In order to prepare the substrate for the ACE assay, triglycine was dansylated
by combining solution A [250 mg triglycine in 25 ml of a 2% (w/v) KHCO3] and
solution B (500 mg dansyl chloride dissolved in 25 ml acetone). The mixture
was stirred for 1 hour at room temperature. The mixture was evaporated to
dryness by freeze-drying 2 ml aliquots which had been frozen in liquid
nitrogen. The synthesized compounds were then dissolved in 40 ml methanol
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and the solution stored at -20 °C. Half of this solution was applied to a 450 x
25 mm glass column filled with 60 g silica powder (Merck Silica gel 60, 0.063-
0.2 mm) suspended in ethyl acetate/iso-propanol/water (v/v ; 4:2:1.2).
Fractions of 1.5 ml were collected. Ten /u\ of each fraction was run on 0.25
mm thin layer chromatography (TLC) plates (Merck) using the same eluent
[ethyl acetate/iso-propanol/water (v/v; 4:2:1.2)] in order to acertain the exact
location of the dansyltriglycine. The resulting fractions were then combined,
frozen in liquid nitrogen and freeze dried. Stock solution was prepared by
dissolving 1.66 mg dansyltriglycine in 500 /A HEPES assay buffer and stored
at -20 °C until further use. The working solution was prepared by diluting the
stock solution to a final concentration of 100 /^g/ml (0.236 mM) in HEPES
assay buffer. Fresh working solution was prepared before each assay.
2.4 Buffers
HEPES assay buffer and the elution buffer for HPLC, sodium phosphate
buffer, were prepared according to the protocols in Appendix 1.
2.5 Angiotensin Converting Enzyme
Five units of angiotensin converting enzyme (ACE) was dissolved in 12.5 ml
demineralized and glass distilled water (1 unit/2500 (A). Aliquots of 0.3 units
(750 /A) of this solution were distributed into 7 ml glass vials and lyophilized.
After lyophilization the enzyme was stored at -20 °C.
When performing the enzyme assay, 0.3 units of enzyme was dissolved in 750
lA HEPES assay buffer.
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2.6 Sensitivity of the Test System as Measured with Captopril
In order to test the sensitivity of the system, the IC50 value for the reference
inhibitor, captopril, was measured. A 57.6 X 10~9 M (in 75 /u\ assay) stock
solution (CS) of captopril was prepared. Working solutions from the stock
solution were prepared (Table 4).













The percentage inhibition of each of the above captopril working solutions was
determined using the ACE assay described in Section 2.8. From the inhibition
results the IC50 of captopril was determined.
2.7 Stopper Solution
Stopper solution (0.1 N Na2EDTA2H2O ) was prepared according to the
protocol in Appendix 1.
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2.8 Enzyme Assay
Twenty five y\ of inhibitor solution or HEPES assay buffer (control) were added
to a 1.5 ml microfuge tube, mixed with 25 /A of enzyme solution and incubated
at 37 °C for 5 minutes. The reaction was started by the addition of 25 /J of
substrate. After 30 minutes of incubation at 37 °C, the reaction was terminated
by the addition of 50 /J 0.1 N Na2EDTA.
For each assay, the blank was replicated twice and the average used for the
subsequent calculations.
2.9 Separation of Substrate (Dansyltriglycine) and Product
(Dansylglycine) using High Performance Liquid
Chromatography
High Performance Liquid Chromatography separations were carried out using
a Varian 5000 instrument linked to a Spectra System UV3000HR detector
using a UV wavelength of 254 nm. Separations were performed using an
analytical Hypersil 5 ODS column which was 25 cm in length and had a 4 mm
internal diameter (ID).
Acetonitrile and 0.01 M phosphate buffer (pH 7.0) were used as the mobile
phase. Isocratic elution with 85% phosphate buffer and 15% acetonitrile
separated the dansyltriglycine from the dansylglycine within 20 minutes at a
flow rate of 1.2 ml min"1. All solvents used were HPLC grade.
2.10 Quantitative Analysis
It was established that the percentage conversion of the substrate by the
enzyme was an accurate method to determine the percentage inhibition of the
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samples. The following formula was used to calculate the percentage
conversion of the substrate:
% Conversion = Peak Area (dansylglycine peak) x100
Peak Area (dansyltriglycine + dansylglycine peaks)
This method assumed that the blank (without the presence on any inhibitors
) would have the highest percentage of the substrate converted. A sample
exhibiting high inhibition levels would have a low percentage of the substrate
converted. Using the following equation, the percentage inhibition of the
sample could be calculated:
% Inhibition = 1 - % conversion (sample) x 100
% conversion (blank)
2.11 Gelatin-Salt Block Test for Detection of Tannins
Plant extract from 200 mg of plant material was dissolved in 4 ml 50 °C
distilled water and allowed to cool. Three to four drops of an aqueous 10%
(w/v) NaCI solution was added to the cooled extract to "salt out" any non-
tannin compounds, thereby eliminating any false-positive tests for tannins. The
resulting solution was filtered and 1 ml of the filtrate was placed into four
shallow white porcelain wells.
Well one served as a control and no reagent was added. Well two had 4 to 5
drops of a 1 % gelatin solution added and the mixture was observed for the
formation of precipitate. Well three had 4 to 5 drops of a solution containing
1 % gelatin and 10 % NaCI added, and the mixture was observed for the
formation of precipitate. Well four had 3 to 4 drops of a 10 % ferric chloride
(FeCI3) solution added, and the mixture was observed for colour produced
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and/or precipitate formation.
2.12 Serial Extraction of Tulbaghia violacea Leaves
In order to determine which solvent to use in the bulk extraction of the
Tulbaghia violacea leaves, finely ground leaves (9 g) from Tulbaghia violacea
were placed in a Soxhiet thimble and extracted with 150 ml hexane using a
Soxhiet extraction apparatus. The hexane was heated to boiling point after
which extraction took place for 2 hours. The extracted liquid was passed
through a Millipore filter (0.44 /urn). The solvent was removed at 37 °C under
vacuum, using a rotary evaporator. The residue was then transferred to a pre-
weighed pill vial. The above process was repeated using ethyl acetate, ethanol
and distilled water.
2.13 Bulk Extraction of the Tulbaghia violacea Leaves
Ground leaves of Tulbaghia violacea (0.7 kg) were extracted in 101 of distilled
water by sonication. The extracted liquid was dried down to 500 ml in front of
a fan. The liquid residue was stored at 4°C.
2.14 Solvent Partitioning of Bulk Extract Residue
The compounds extracted during the bulk extraction were partitioned against
a wide range of solvents in order to further separate the active compounds.
Twenty ml of the water fraction was partitioned with either hexane, diethyl
ether or butanol. It was established that the active compounds were extracted
using butanol. The compounds extracted in the bulk extract were diluted to 1
I and partitioned against 1 I butanol. This process was repeated five times to
yield 5 I of butanol containing the active compounds. The butanol was
removed under reduced pressure, using a rotary evaporator. The liquid
30
residue was stored at -20 °C until further use.
2.15 Separation of Extracted Compounds using Cation Exchange
Resin Chromatography
Forty grams of Dowex 50W-X8 was loaded into a 580 x 28 mm column. The
13.5 g of gum which had been extracted in butanol was dissolved in 20 ml
dH2O (pH 3.5) and loaded onto the column. It was firstly eluted with 80%
ethanol until the elution was clear, followed by 5N ammonium hydroxide. The
ammonium hydroxide was removed under reduced pressure, using a rotary
evaporator. The residue was stored at -20 °C until further use.
2.16 Sephadex ® LH-20 Separation of Extracted Compounds
One hundred grams of Sephadex ® LH-20 was swollen in 10% methanol for
5 hours. It was then loaded onto a 760 x 24 mm column and allowed to settle
overnight. One third of the sample (0.82 grams) was loaded and fractions of
8 ml collected over 15 minutes. The resulting fractions were then tested for
ACE inhibitory activity , and the active fractions combined and brought to
dryness under reduced pressure, using a rotary evaporator. The residue was
stored at -20 °C until further use.
2.17 HPLC Methods
All solvents used were HPLC grade. Separations and detection took place
using a Varian 500 instrument and Varian detector respectively, at a UV
wavelength of 200 nm. A semi-preparative Hypersil column (250 mm X 4 mm
ID) was used to separate the fractions at a flow rate of 2.5 ml min"1. Two
programs were used to separate the compounds:
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Programi: Solvent A: dH2O; Solvent B: Acetonitrile: elution conditions: linear
gradient 100% A to 80% A over 20 minutes; isocratic 80% A for 15 minutes.
Program 2: Solvent A: dH2O; Solvent B: Acetonitrile: elution conditions:





3.1 Optimisation of Assay and Conditions for Quantitative
Analysis
The experimental parameters such as the NaCI and HEPES-buffer
concentrations, pH, and the UV detection of dansylglycine had been optimised
by ELBL and WAGNER (1991).
The HPLC method, however, had to be optimised for the equipment available
in this study. According to ELBL and WAGNER (1991) the dansyltriglycine and
dansylglycine could be separated within 23 minutes utilising a gradient HPLC
method. HANSEN, NYMAN, WAGENER SMITT, ADSERSEN, GUDIKSEN,
RAJASEKHARAN and PUSHPANGADAN (1993) described a method which
could separate both the product and substrate within 7 minutes. This method
was tested, but a similar separation could not be achieved. Utilising the
program described in Section 2.9, the substrate, dansyltriglycine was
separated from the product, dansylglycine within 20 minutes (Figure 4).
Utilising an isocratic system ensured that there was no delay in injecting




















0 5 10 15 20 25
Retention time (minutes)
Figure 4: Chromatogram showing the HPLC separation of dansyltriglycine
from dansylglycine.
3.2 Rate of Enzymatic Reaction
In order to carry out the ACE inhibitory test, the reaction must proceed at a
rate that can be conveniently measured, and this rate must remain constant
for a sufficient period of time. The quantity of substrate required to establish
this condition must be determined under standardized conditions. Thus
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variable parameters such as molarity and pH of the incubation buffer,
temperature and enzyme concentration were kept constant. ELBL and
WAGNER (1991) tested the time course of the enzyme reaction using three
different substrate concentrations, and found a concentration of 0.236 mM to
be ideal. This was the substrate concentration used for the duration of this
study.
The time course action of the enzyme was determined by reacting
dansyltriglycine at a concentration of 0.236 mM with the ACE enzyme and
varying the incubation time. By plotting the percentage conversion of
dansyltriglycine to dansylglycine against time, it was possible to see over what
time period the enzymatic activity was constant. From Figure 5 it can be seen
that the enzymatic rate was constant over a period of 35 minutes. Both ELBL
and WAGNER (1991) and HANSEN, NYMAN, WAGENER SMITT,
ADSERSEN, GUDIKSEN, RAJASEKHARAN and PUSHPANGADAN (1993)
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Figure 5: The time course of the ACE reaction.
The correlation coefficient for each time was calculated. According to the data
in Table 5 a time of 35 minutes was chosen as the ideal incubation time.
Table 5: Correlation coefficients calculated at specific incubation times during


















3.3 Establishing the Sensitivity of the Assay System
The IC50 value of an inhibitor is dependant upon inhibition mechanisms and
assay conditions used and may vary from one laboratory to another, but is
useful for comparing activities within a set of determinations (BUSH, 1983).
The sensitivity of the assay was tested by determination of the IC50 value of the
competitive inhibitor captopril and comparing the values cited in the literature
(Figure 6). From the data an IC50 value of 17.7 nM was established. HANSEN,
NYMAN, WAGENER SMITT, ADSERSEN, GUDIKSEN, RAJASEKHARAN
and PUSHPANGADAN (1993) found theirs to be 11 nM; ELBL and WAGNER
(1991) 14 nM, while CUSHMAN, CHEUNG, SABO and ONDETTI (1977)
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established a value of 23 nM. Thus, the system used in this study was not as
sensitive as that used by ELBL and WAGNER (1991), but more sensitive than





Figure 6: Inhibition of ACE by the reference inhibitor captopril at varying
concentrations. The IC50 value was determined to be 17.9 nM.
3.4 Calculation of the Percentage Inhibition of Samples Tested in
the Assay
Both HANSEN, NYMAN, WAGENER SMITT, ADSERSEN, GUDIKSEN,
RAJASEKHARAN and PUSHPANGADAN (1993) and ELBL and WAGNER
(1991) made use of an internal standard in their assay system to quantify the
amount of product formation. From this they were able to calculate the
percentage inhibition of the test compounds introduced into the assay.
Determining the percentage inhibition utilising this method was inconsistent,
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and a new method was developed (Section 2.10) that did not necessitate the
addition of an internal standard.
In order to test the variability of the new method, three replicates comprising
eight samples were carried out on three different days (Table 6).
Table 6: Investigation of the percentage conversion of dansyltriglycine to















































The data within each treatment was uniform. Although the absolute difference
between the replicates is very small there is a significant difference which is
due to the uniformity within each treatment.
3.5 Concentration of the Plant Extract in the Assay
A concentration of 0.33 mg ml"1 assay volume (as proposed by ELBL and
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WAGNER, 1991) was used in the assay and only plants exhibiting an
inhibition of greater than 50 % were further investigated. At this concentration,
false positive results due to nonspecific interaction of ubiquitous components
like chlorophyll, tannins and different acids could practically be excluded.
Concentrations ranging from 0.2 mg ml'1 to 3.3 mg ml"1 have been utilised
(HANSEN, NYMAN, WAGENER SMITT, ADSERSEN, GUDIKSEN,
RAJASEKHARAN and PUSHPANGADAN, 1993).
3.6 Screening of Plants for ACE Inhibitory Activity
According to ABRAMS, DAVIES and FERGUSON (1984), the principal
pharmacological effects of ACE inhibitors are vasodilatory, increased sodium
excretion, diuresis and lowering of blood pressure. Plants chosen for this study
were thus selected based on their traditional usage in the treatment of
hypertension and as diuretics. Plants used for the treatment of cardiovascular
diseases were also of interest for screening for ACE inhibitory activity. Results
of plant extracts screened to determine their level of ACE inhibition are shown
in Table 7. Both ethanolic and aqueous extracts were tested in the assay.
These are the two main solvents available to traditional healers in South Africa
and would thus follow their extraction methods more closely.
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Table 7: Plants screened for the presence of angiotensin converting enzyme
(ACE) inhibitors. Aqueous and ethanolic extracts were tested .
* Indicates inhibition levels greater than 50% that were tested for
tannins in the Gelatin-Salt Block Test.
Plant Name
Adenopodia spicata (E. Mey.) Presl
Adiantum capillus-veneris L
Agapanthus africanus (L) Hoffmg.
Agave americana L.
Catha edulis (Vahl) Forssk. ex Endl.
Cannabis sativa L
Clausena anisata (Willd.) Hook. f.
ex Brnth.








































































Protorhus longifolia (Bernh.) Engl.
Rhus chirindensis Bak. f.
Sclerocarya birrea (A. Rich.)
Hochst. Subsp. caffra (Sond.)
Kokwaro












































The highest inhibition (97%) of ACE was recorded for Adenopodia spicata
leaves. A further seven extracts exhibited inhibition greater than 70% and five
over 50%. It was interesting to note that in most cases the leaves of the plants
were found to be the most active.
Plants exhibiting inhibition levels of greater than 50% (marked with asterisks
in Table 7) were further investigated and subjected to a literature search in
order to get a composite picture of compounds that have already been isolated
from them, other known uses the plant has, and a detailed report (if available)
of how the plant is administrated to the patient for the treatment of
hypertension. The results are presented below:
4-1
The underground caudex [swollen stem base] of Stangeria eriopus is used for
magico-medicinal purposes by certain ethnic groups in South Africa. In a
survey carried out in July 1992 at the two largest traditional medicine markets
at Durban and Isipingo involving a total of 170 gatherer-vendors, the 28 people
trading in Stangeria eriopus were asked to assess the monthly amount of plant
material sold, and to comment on the range of plant uses by the customers.
Twelve Zulu herbalists were also interviewed concerning plant usage. A total
of 3 410 plants were sold during the month of July at both markets, indicating
that plant conservation actions are urgently needed. In a biochemical study,
the dried caudices of Stangeria eriopus plants were found to be contain 85.1 %
carbohydrate, 6.1% protein, 6.1% fibre, 2.4% ash and 0.3% fat. The ratio of
sitosterol to stigmasterol was 4:1; the main fatty acids were palmitic, oleic,
stearic and arachidic acids. Twelve amino acids were identified, including
(3-alanine, Y-aminobutyric acid and pyroglutamic acid. The high concentration
of sodium sulphate was thought to be responsible for the efficacy of Stangeria
eriopus as an emetic. The toxins cycasin (0.21% DW) and macrozamin were
also identified in the caudex (OSBORNE, GROVE, OH, MABRY, NG and
SEAWRIGHT, 1994).
Agave americana is used by theXhosafor high blood pressure (HUTCHINGS,
SCOTT, LEWIS and CUNNINGHAM, 1996). Agave attenuata, Agave
lophantha and Agave legrellianan have been studied for molluscicide activity.
In China, hecogenin and tigogenin from Agave spp., are used as industrial
precursors for the partial synthesis of steroidal drugs (CHEN and WU, 1994).
Agapanthus africanus is an indigenous plant which is also used in traditional
herbal remedies during pregnancy and childbirth (VEALE, FURMAN and
OLIVER, 1992). A crude decoction was tested for pharmacological activity on
the isolated rat uterus and ileum. Agapanthus africanus exhibited direct
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smooth muscle activity on the uterus and ileum preparations. Hot root
infusions of Agapanthus africana are taken daily as emetics for heart disease
(BRYANT, 1966). Known chemical constituents are sitosterol, yuccagenin and
agapanthagenin. The steroid spirostan sapogenins, 7-, 8(14)- and 9(11)-
dehydroagapanthagenin have been isolated from the rhizomes (GONZALEZ,
FREIRE, GARCIA, SALAZAR and SUAREZ, 1974).
Known chemical constituents isolated from Tulbaghia violacea include sulfhur
compounds, 2,4,7-tetrathiaoctane-2.2-dioxide and 2,4,5,7-tetrathiaoctane,
fifteen flavones, including theflavonols kaempferol and quercetin and several
sugars and steroidal saponins (BURTON, 1990). Bacteriostatic activity has
been shown in the aqueous extracts from various parts of the plant. The
presence of a P-adreneric agonist with inhibitory effects on normal muscle
contractions was indicated in experiments with the extracts on isolated smooth
muscle preparations (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM,
1996).
Infusions made from the inner part of the rhizomes of Dietes iridioides are
taken orally or in enemas and are used in childbirth and against hypertension
(PUJOL, 1990).
Unspecified parts of Protorhus longifolia are used by herbalists as medicine
to strengthen the heart (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM,
1996). The bark yielded 10.2 -18% tanning material and 7% tannin (WATT
and BREYER-BRANDWIJK, 1962).
Rhus chirindensis is used by herbalists as a medicine for heart complaints
(HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). The bark is also
used to stimulate circulation and rheumatism (PUJOL, 1990). A flavone from
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the roots of Rhus undulata was identified as apigenin dimethylether (FOURIE
andSNYCKERS, 1984).
The bark of Sclerocarya birrea is taken as a tea twice a day to strengthen the
heart (HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). Bark
decoctions are taken in West Africa to treat diarrhoea. A lyophilized decoction
of material collected in Burkina Faso showed significant activity against 2
models of experimentally-induced diarrhoea (GALVEZ, ZARZUELO,
CRESPO, UTRILLA, JIMINEZ, SPIESSENS and DE WITTE, 1991). Fruits are
aromatic and edible, but are also reported to be potent insecticides and to
have possible disinfectant properties (BRYANT, 1966). A condensed tannin
isolated from the crude drug inhibited intestinal mobility; its monomer, obtained
by acid hydrolysis, was identified as procyanidin C1 (GALVEZ, ZARZUELO,
CRESPO, UTRILLA, JIMINEZ, SPIESSENS and DE WITTE, 1991).
Roots of Adenopodia spicata are used for sharp pains in the chest
(HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). Root decoctions
are also taken by the Mfengu for sharp, non-tubercular pains in the chest. The
roots contain saponins (WATT and BREYER-BRANDWIJK, 1962).
Emetics made from boiling a handful of leaves from Mesembryanthemum sp.
are administered for fearful dreams believed to be symptomatic of heart
weakness (BRYANT, 1966).
Wood smoke and the steam from boiling the leaves of Clausena anisata are
used to cleanse the body internally. Such procedures are also thought to
strengthen the heart. Root decoctions are taken in doses of half a wine glass
twice a day for heart ailments (PUJOL, 1990). The glandular leaves are strong
smelling, particularly when crushed. Many terpenoid hydrocarbons,
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sequiterpenoids and fatty acids have been isolated from pericarps, roots and
leaves (REISCH, ADESINA, BERGENTHAL, and HUSSAIN, 1985). The
leaves of Clausena anisata are widely used as an insect repellent and the root
has molluscicidal effects (ADESINA and ADEWUNMI, 1985).
The inner bark of Dombeya rotundifolia is used to treat weakness of the heart
(HUTCHINGS, SCOTT, LEWIS and CUNNINGHAM, 1996). There appears to
be no published information on the chemical composition oWombeya species
( Dictionary of Natural Products on CD-ROM, release 4:2; 1996).
3.7 Determination of False Positives
The inhibition of ACE by the plant extract could be due to many factors, such
as a specific, highly active compound present in small amounts; one or many
compounds with low activity present in large amounts; or unspecific inhibitory
compounds like tannins interacting with the enzyme. In many laboratories, the
inhibitory activity of plant extracts has been reported to be due to tannins, or
a mixture of tannins and compounds with low inhibitory activity. KNUDSEN
and LANGHOFF (1995) illustrated this point where in an investigation of 32
Indian plant species, 10 plants showed inhibitory activity. After the precipitation
of the tannins with gelatin, only one plant showed significant activity.
The thirteen plants inhibiting ACE by 50 % or more were tested for the
presence of tannins using the gelatin-salt block test described in Chapter 2.
The results are presented in Table 8.
3.7.1 Interpretation of Resultant Reactions
The reaction with ferric chloride has been used widely to identify phenolic
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compounds, but it is non-specific and therefore of little value in distinguishing
between different chemical classes in crude extracts. It gives a greenish colour
with catechol derivatives (ortho dihydroxy phenols) and a blue colour with
pyrogallol derivatives (3,4,5-trihydroxy phenols). If a deep blue-black colour
appears, it is indicative of the presence of a 3,4,5-trihydroxy phenol, but the
formation of a green colour does not necessarily indicate the absence of this
group or the presence of a catechol group (ROBINSON, 1975). Thus, caution
should be exercised when interpreting the results from the reaction with ferric
chloride as described below:
No reaction with ferric chloride solution indicates that no tannins or phenolic
compounds are present in the plant extract. A greenish-blue or greenish-black
colour after the addition of ferric chloride (assuming that precipitation was
noted after the gelatin-salt block test) indicates the presence of tannins of the
condensed type. Bluish-black colour after the addition of ferric chloride
(assuming that precipitation was noted after the gelatin-salt block test)
indicates the presence of tannins of the pyrogallol type. A negative gelatin-salt
block test (no precipitate), but colours produced (either greenish or blue-black)
after the addition of ferric chloride solution, indicates that there were no
tannins present. In these cases colour changes were induced by other
phenolic plant constituents.
As can be seen from Table 8 , seven of the thirteen plants investigated
produced a negative gelatin-salt block test. Out of these five, Agave
americanus did not react with the ferric chloride and it could be concluded that
its inhibiting properties were not due to the presence of tannins nor to other
phenolic plant constituents. It was interesting to note that the results for plants
showing positive reactions for the presence of tannins in Table 8 are in
agreement with reports in the literature.
Table 8: Results obtained when plant extracts exhibiting levels greater than
50% ACE inhibitory activity were tested for the presence of tannins






















































































Key: N.P. No precipitate P, Precipitate
The bark of Protorhus longifolia yields tanning material and tannin (WATT and
BREYER-BRANDWIJK, 1962). Although not much is known about the
chemical composition of Rhus chirindensis, tannins have been found in the
bark and twigs of Rhus laevigata (WATT and BREYER-BRANDWIJK, 1962).
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The gum of Sclerocarya birrea is rich in tannins. Tannins are also present in
the leaves of the plant (GUEYE, 1973 cited in OLIVER-BEVER, 1986).
3.8 Selection of Plant for Bioassay-Guided Isolation of Active
Compound(s)
It was decided to use the leaves of Agave americanus for further
investigation. Unfortunately, when new material was obtained, its ability to
inhibit ACE was vastly reduced when compared to the earlier results. Further
investigation showed that plant material remaining from the first collection still
exhibited high inhibition levels (Table 9). It was concluded that the most likely
cause for the loss of activity was seasonal variations in secondary plant
metabolites, with the active plant material being collected in summer, and the
inactive plant material in winter. A seasonal variation in the ACE inhibiting
properties of Dietes iridioides was also established. The inhibitory properties
of leaves harvested in winter differed from those harvested in summer (Table
9).
•?.
Table 9: Percentage inhibition of ACE by Agave americana and Dietes
























After further testing of plants that had displayed a negative gelatin-salt block
test, it was decided that further investigations be made using Tulbaghia
violacea, which was collected in June from the National Botanical Gardens,
Pietermaritzburg.
3.9 Establishment of the Optimum Extracting Solvent
A serial extraction was carried out using hexane, ethyl acetate, ethanol and
dH2O successively (Section 2.12). This was carried out in order to determine
which solvent extracted the compound(s) inhibiting ACE. The results of the
assay can be seen in Table 10.
Table 10: Percentage inhibition of ACE by extracts obtained by using various












As can be seen in the above Table, the aqueous extract gave the highest
inhibitory result.
3.10 Testing Stability of the Aqueous Extract
The aqueous extract was boiled for 1 hour to determine its stability before the
bulk extraction was made. The percentage inhibition of the resultant fraction
was calculated using the ACE assay (Table 11).








Its was interesting to note that boiling the extract lead to an insignificant loss
of inhibitory activity. It was thus concluded that the activity of the sample was
not due to the presence of peptides or proteins, which would have denatured
during boiling.
3.11 Bulk Extraction
Dried and finely ground Tulbaghia violacea leaves (0.7 kg) were extracted in
101 dH20 by sonication (Section 2.13). The extraction was successful, with the
resulting residue exhibiting 90 % inhibition in the ACE assay.
As aqueous extracts posses certain difficulties in normally used purification
techniques, it was decided to partition the aqueous extract against a range of
solvents in order to establish whether or not the activity moved into an organic
phase.
3.12 Solvent Partitioning of the Aqueous Extract
Portions of the bulk extract (20 ml) were partitioned against hexane, diethyl
ether and butanol individually. The resultant residues were assayed in order
to determine the solvent which was to be used to partition the bulk aqueous
extract (Table 12).
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The compounds partitioning into butanol gave the highest ACE inhibition. The
aqueous extract against which butanol was partitioned still exhibited ACE
inhibitory activity of 70%.
The butanol fraction was taken to dryness, yielding 13.5 grams of a gum. The
aqueous extract was dried under reduced pressure, and the resultant residue
stored at - 20°C until further use.
3.13 Cation Exchange Resin Chromatography of the Active Butanol
Fraction
The 13.5 grams of gum obtained after drying the butanol fraction was
dissolved in 20 ml dH2O (pH 3.5) and fractionated using cation exchange resin
chromatography (Dowex 50W-X8). The column was washed with copious
amounts of 80% ethanol. This was followed by 5N ammonium hydroxide to
remove the absorbed compounds. The ethanolic and ammonium hydroxide
fractions were collected, taken to dryness and assayed (Table 13).
As can be seen in Table 13, compounds exhibiting ACE inhibitory activity were
limited to the ammonium fraction. Compounds present in the ethanolic fraction
exhibited no ACE inhibitory activity, whilst comprising 82% of the initial butanol
factions obtained. Using the cation exchange resin chromatography step thus
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proved to be a particularly powerful step in removing non-active impurities.











3.14 Fractionation of the Ammonium Residue by Sephadex® LH-20
The ammonium residue (2.46 g) was purified by Sephadex ® LH-20 using
10% methanol as eluent. One hundred fractions were collected, and initially
every fifth fraction assayed. After establishing the region of activity, all fractions
within the region were assayed. Fractions 13-17 exhibited inhibition greater
than 80% and were thus combined and evaporated to dryness under nitrogen
leaving a dry residue of 250 mg in weight. This residue was subjected to
several TLC systems. No successful separation was attained. Due to the
hydrophilic nature of the compounds, it was not expected that they could be
separated by normal-phase silica gel chromatography. It was thus decided to
proceed directly to reverse phase HPLC.
3.15 Separation of the Active Residue using HPLC Techniques
The residue collected after the Sephadex purification step (Fractions 13-17)
was re-suspended in dH2O and fractions of 50 //I (5 mg) were fractionated by
HPLC (Semi-preparative Hypersil column; 2.5 ml min"1 flow rate; UV
wavelength 200 nm; Solvent A: dH2O; Solvent B: Acetonitrile: elution
conditions: linear gradient 100% A to 80% A over 20 minutes; isocratic 80%
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Figure 7: Chromatogram showing the separation of the active residue
obtained after Sephadex purification (Fraction 13-17) by HPLC.
As can be seen in the above chromatogram, the residue yielded many UV-
peaks. These were grouped together into three Fractions, namely A, B, and
C. Each Fraction was collected, taken to dryness and assayed (Table 14).
Table 14: Percentage inhibition of ACE by Fractions A, B and C obtained
following HPLC of the active Fraction collected after Sephadex









Fraction B exhibited the greatest ACE inhibition activity. It was thus decided
to attempt to isolated the active compound(s) from this fraction by further
HPLC.
Ten mg of the residue (Fraction B) was fractionated using HPLC (Semi-
preparative Hypersil column; 2.5 ml min"1 flow rate; UV wavelength 200 nm;
Solvent A: dH2O; Solvent B: Acetonitrile: elution conditions: isocratic 100% A
for 20 minutes; linear gradient 100% A to 80% A over 10 minutes). Fractions
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Figure 8: Chromatogram showing the separation of Fraction B by HPLC and the
UV spectra of Fraction 2, the most active fraction.
Table 15: Percentage inhibition of ACE by Fractions 1 to 6 collected after
fractionation of Fraction B by HPLC.















As can be seen from Table 15, Fractions 1 and 2 exhibited significant levels of
ACE inhibition, although not as high as the levels in Fraction B. This could be
due to the synergistic nature of the compounds that were separated.
A diagramatic representation of the procedures used to fractionate the residue
from the bulk extract up to this point is summarized in Figure 9.
Ground Tulbaghia Leaves (0.7 kg)
i
Bulk extraction with dH2O (not weighed)
Butanol partitioning (13.5 g)
I
Cation exchange resin chromatography (2.46 g)
Sephadex ® LH-20 using 10% MeOH as eluent (0.25 g)
y
HPLC step 1 (39.7 mg)
Figure 9: Flow diagram illustrating the purification steps and the amount of
active fraction recovered after each step.
Due to time constraints, the remainder of Fraction B was not fractionated into
Fractions 1 and 2. Further purification will take place, but the results won't be
presented in this study.
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3.16 ACE inhibitory Compounds Isolated from Plants in Previous
Studies and Chemical Properties of Fraction 2
Angiotensin converting enzyme inhibitors were first isolated from plants in the
mid 1980's. Since then, approximately 82 compounds exhibiting ACE inhibitory
activity have been isolated, comprising mainly of proanthocyanindins,
flavonoids, terpenes, peptides and amino acids. Hydrolysable tannins,
phenylpropanes, xanthones, fatty acids and alkaloids are represented, but not
to the same extent (HANSEN, 1995). In an attempt to get a better idea about
the compound(s) causing ACE inhibition in this study, the chemical properties
of Fraction 2 (Section 3.15) are discussed.
The active fraction is hydrophilic. After boiling for 1 hour no loss in ACE
inhibitory activity was noted. It does not exhibit any fluorescing properties when
applied on a TLC plate and observed under 254 and 365 nm. Analysis of TLC
plates using anisaldehyde and 20% H2SO4 as spray reagents gave no results.
Amino acids were tested for by spoting the fraction on a TLC plate and spraying
with ninhydrin spray reagent. The results were negative. Tannins were tested
for using the gelatin-salt block test. The results were negative. Poly-phenolic
compounds were tested for using FeCI3. This test was also negative. The
fraction was eluted off a reverse phase HPLC column with H2O as the mobile
phase within 7 minutes confirming its hydrophilic nature. Using the
characteristics discussed above, groups of naturally-occurring compounds have
been eliminated.
Both simple and furano coumarins as well as flavonoids have been eliminated
as these compound groups always fluoresce at 365 nm. Xanthones have been
eliminated on the basis that their distinctive UV spectrum does not match the
one obtained for the active region (Figure 8). Steroids and fatty acids are not
hydrophilic and thus would not be eluted off a reverse phase column using H2O
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as the mobile phase. Proteins and peptides have already been discounted due
to the fact that the activity of the fraction is not lost through boiling (Section
3.10). Amino acids , tannins and poly- phenolic compounds were eliminated
through specific tests.
Groups of natural compounds which could not be eliminated were saponin
glycosides, polyacetylenes, chromene glycosides or other low molecular weight
glycosides. This is due to the hydrophilic nature of the glycosides and their UV




Twenty plants that are routinely used by Zulu traditional healers for the
treatment of hypertension were assayed to determine their levels of
angiotensin converting enzyme (ACE) inhibitory activity. Out of the twenty
plants assayed, eight exhibited ACE inhibitory levels greater than 70% with a
further five over 50%, giving a 65 % hit rate. Both aqueous and ethanolic
extracts exhibited high levels of ACE inhibition. These two extractants would
be the most freely available to traditional healers, and thus most extensively
used. Other plants used by traditional healers could not be obtained, and thus
there is still a wealth of plants to be tested for their ACE inhibitory activity.
The presence of a strong ACE inhibitory activity does, however, not
necessarily imply that the species could provide powerful anti-hypertensive
drugs. As discussed by WAGNER, ELBL, LOTTER and GUINEA (1991),
some flavonoids may show an in vitro activity due to the generation of chelate
complexes within the active centre of ACE. It must be remembered that if the
plant exhibits low levels of ACE inhibitory activity, that it may act on a different
mechanism causing hypertension and could thus be used as a anti-
hypertensive agent.
The ACE bioassay, which was set up during this study, yielded results that
were constant and reproducible. This makes further research into ACE
inhibitory compounds more feasible.
59
The separation techniques used in this study proved to be very efficient in the
fractionation of compounds from the original sample. The results obtained
using the techniques were very reproducible. This would aid further attempts
to isolate the active compound(s) from Tulbaghia violacea in the future.
It was unfortunate that due to time constraints the compound(s) extracted from
Tulbaghia violacea that inhibited ACE were not isolated. Steps that still
require attention in future are further HPLC separation and GCMS analysis,
after which the isolated compounds could undergo structural elucidation a
task beyond the scope of this M.Sc project.
Other plants that showed promise were Agave americana and Dietes
iridioides. It was unfortunate that they both showed seasonal variation with
respect to their inhibitory activity and could not be further investigated in this
study. Further studies into ACE inhibitory compounds from plants could thus
start with these two promising plants.
Within the wealth of plants in South Africa, there lies an untapped reservoir of
potentially useful chemical compounds, unique templates that could serve as
starting points for analog preparation by chemists, or as interesting tools that
can be applied to achieve a better understanding of biological processes
involved in hypertension.
The process of isolating pharmacologically-active compounds from plants in
their pure form is often long, troublesome and requires a multi-disciplinary
approach. Projects need to run concurrently to test toxicity of active
compounds as well as to make the results available to the traditional healers,
without whose knowledge studies such as this would take many more years
to complete.
so
FARNSWORTH (1984) summed it up as follows: The discovery of useful
drugs from plants will be best carried out through a concentrated multi-
disciplinary attack on the plant kingdom by means of collaboration, good
planning, imaginative and creative thinking, dedication, a touch of luck, and a
great deal of serendipity.
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HEPES-NaOH (50 mM) (11.92 g) and 17.52g NaCI (300 mM) were added to
900 ml deionised distilled water and the pH adjusted to 8.0 with NaOH. The
final volume was made up to 1 I.
Elution Buffer for HPLC
Stock solution A was prepared by dissolving 15.601 g (0.1 M) of monobasic
sodium phosphate (NaH2PO4) in distilled water to a total volume of 1 I. Stock
solution B was prepared by dissolving 14.196 g (0.1 M) of dibasic sodium
phosphate (Na2HPO4) in distilled water to a total volume of 1 I. By mixing 50
ml of A and 50 ml of Band diluting to a total of 1 I a phosphate buffer (0.01M)
of pH 7.0 was prepared. The buffer was then filtered through a 0.22 /̂ m filter.
Stopper Solution
Na2EDTA.2H2O (3.72 g) was dissolved in 100 ml distilled water (0.1 N).
